Jacobs Levy Equity Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Jacobs Levy Equity Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-82,139	Closed	-$6.01M	–	1176
2020 Q4	$6.01M	Buy	82,139 +69,022	+526%	+$5.13M	0.05%	368
2020 Q3	$1.02M	Buy	+13,117	New	+$903K	0.01%	663
2019 Q3	–	Sell	-18,700	Closed	-$450K	–	1059
2019 Q2	$450K	Sell	18,700 -270,839	-94%	-$6.87M	0.01%	755
2019 Q1	$7.65M	Sell	289,539 -31,800	-10%	-$754K	0.11%	249
2018 Q4	$6.28M	Buy	321,339 +129,410	+67%	+$2.54M	0.11%	209
2018 Q3	$3.76M	Buy	191,929 +7,323	+4%	+$139K	0.05%	374
2018 Q2	$3.06M	Buy	184,606 +100,106	+118%	+$1.53M	0.05%	412
2018 Q1	$1.2M	Buy	84,500 +18,600	+28%	+$275K	0.02%	597
2017 Q4	$962K	Buy	+65,900	New	+$926K	0.02%	623

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Jacobs Levy Equity Management's HZNP Position: Q1 2021 in Review

Jacobs Levy Equity Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021, closing a stake of 82,139 shares — an estimated $6.01M sold.

Jacobs Levy Equity Management first reported a position in HZNP in Q4 2017 and held it in 9 quarters. The position peaked at $7.65M in Q1 2019. 517 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

Jacobs Levy Equity Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 82,139 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $6.01M.
Jacobs Levy Equity Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 9 quarters.
Jacobs Levy Equity Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.65M in Q1 2019.
517 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2021, filed 17 May 2021.